Pendulum Therapeutics Enhances Collaboration with Mayo Clinic for Women's Health Research
Pendulum Therapeutics, a leading biotechnology firm innovating in microbiome science, has announced an important expansion of its clinical research collaboration with the esteemed Mayo Clinic. This collaboration aims to investigate new microbiome-based therapeutic approaches specifically tailored for women's health and dermatology. The partnership, which builds on their existing relationship established in 2013, showcases a mutual dedication towards advancing thorough and evidence-based research in the microbiome field.
The upcoming phase of this collaboration will include a series of clinical trials led by Mayo Clinic's expert investigators. These trials will focus on exploring the effects of microbiome-based interventions on bone health in patients receiving treatment for breast cancer. Additionally, cutting-edge research will delve into the gut-skin axis and how the microbiome can play a crucial role in enhancing the transition through menopause.
Pendulum's portfolio of microbiome-targeted products will be central to these studies. Utilizing the company's expertise in strain isolation, anaerobic manufacturing, DNA sequencing, and rigorous clinical validation, the research aims to uncover intricate connections between the microbiome and systemic health.
Colleen Cutcliffe, PhD, Co-founder and CEO of Pendulum Therapeutics, emphasized the collaboration's role in pushing the boundaries of microbiome science, highlighting that, "Our collaboration represents an important milestone in the continued advancement of microbiome science." Dr. Cutcliffe elaborated that their joint effort aims to deepen the understanding of the critical influence the gut microbiome has on various aspects of health, ranging from metabolic processes to skin wellness and women's health.
This renewed commitment to microbiome research comes on the heels of Pendulum's successful history in developing clinical products. For example, Pendulum Glucose Control stands as the first probiotic clinically validated to significantly reduce A1C levels in individuals with type 2 diabetes. This precedent has solidified Pendulum’s reputation in the healthcare field, bringing an innovative approach to microbiome applications in various health segments.
Pendulum Therapeutics, founded in 2012 by a group of scientists from prestigious institutions including Harvard, Stanford, UC Berkeley, and Johns Hopkins University, continues to be a trailblazer in utilizing cutting-edge microbiome research to create targeted microbial solutions that enhance human health. While the company is recognized for its contributions to metabolic health, it aims to explore broader applications in preventive and therapeutic care across the healthcare spectrum.
For more information about Pendulum Therapeutics and its groundbreaking work in microbiome science, individuals are encouraged to visit www.pendulumlife.com. It is important to note that Mayo Clinic retains a financial interest in the innovative technology discussed in this announcement, and will channel any generated revenue towards its non-profit mission dedicated to enhancing patient care, education, and research.
The upcoming phase of this collaboration will include a series of clinical trials led by Mayo Clinic's expert investigators. These trials will focus on exploring the effects of microbiome-based interventions on bone health in patients receiving treatment for breast cancer. Additionally, cutting-edge research will delve into the gut-skin axis and how the microbiome can play a crucial role in enhancing the transition through menopause.
Pendulum's portfolio of microbiome-targeted products will be central to these studies. Utilizing the company's expertise in strain isolation, anaerobic manufacturing, DNA sequencing, and rigorous clinical validation, the research aims to uncover intricate connections between the microbiome and systemic health.
Colleen Cutcliffe, PhD, Co-founder and CEO of Pendulum Therapeutics, emphasized the collaboration's role in pushing the boundaries of microbiome science, highlighting that, "Our collaboration represents an important milestone in the continued advancement of microbiome science." Dr. Cutcliffe elaborated that their joint effort aims to deepen the understanding of the critical influence the gut microbiome has on various aspects of health, ranging from metabolic processes to skin wellness and women's health.
This renewed commitment to microbiome research comes on the heels of Pendulum's successful history in developing clinical products. For example, Pendulum Glucose Control stands as the first probiotic clinically validated to significantly reduce A1C levels in individuals with type 2 diabetes. This precedent has solidified Pendulum’s reputation in the healthcare field, bringing an innovative approach to microbiome applications in various health segments.
Pendulum Therapeutics, founded in 2012 by a group of scientists from prestigious institutions including Harvard, Stanford, UC Berkeley, and Johns Hopkins University, continues to be a trailblazer in utilizing cutting-edge microbiome research to create targeted microbial solutions that enhance human health. While the company is recognized for its contributions to metabolic health, it aims to explore broader applications in preventive and therapeutic care across the healthcare spectrum.
For more information about Pendulum Therapeutics and its groundbreaking work in microbiome science, individuals are encouraged to visit www.pendulumlife.com. It is important to note that Mayo Clinic retains a financial interest in the innovative technology discussed in this announcement, and will channel any generated revenue towards its non-profit mission dedicated to enhancing patient care, education, and research.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.